Model-based comparison of maternal and foetal organ doses from (99m)Tc pertechnetate, DMSA, DTPA, HDP, MAA and MAG(3) diagnostic intakes during pregnancy.
Organ residence times were calculated for diagnostic intakes of (99m)Tc pertechnetate, 2,3-dimercaptosuccinic acid (DMSA), diethylene triamine penta-acetic acid (DTPA), hydroxymethylene diphosphonate (HDP), macroaggregated albumin (MAA) and mercapto-acetyltriglycine (MAG(3)) during the 1st and 3rd stages of pregnancy and used with the MIRDOSE3 pregnant female phantoms for generation of dose estimates. At stage 3 individual foetal organ doses were estimated via a surrogate phantom based on that for the new-born but with mean dose/cumulated activity ( S) values scaled for compatibility with foetal whole body S. Stage 1 or 3 whole foetus doses ranged from 5.2 to 0.77 microGy MBq(-1) respectively, analogous to current ICRP estimates for these agents using similar in vivo biodistribution model databases. Most stage 3 maternal and foetal organ doses were similar within a factor of 3, being higher in the foetus than the mother with pertechnetate, DTPA and MAG(3), and lower with DMSA, HDP and MAA. Doses were more uniformly distributed among foetal organs than in the mother. Placental transfer was greatest with pertechnetate, where dose to the stage 3 foetal thyroid was 60-140 microGy MBq(-1). With each agent there was more placental transfer in stage 3 than in stage 1, but doses to stage 1 whole foetus were always higher, with the contribution from the mother dominant. For DMSA, HDP and MAG(3) the maternal contribution to total foetal body dose exceeded 93% for both stages.
Saunders
Margaret
M
Centre for Physics and Engineering Research in Medicine, University of Bristol, Bristol Oncology Centre, Horfield Road, Bristol BS2 8ED, UK.
Palmer
Maria
M
Preece
Alan
A
Millard
Roger
R
D000818:Animals; D005260:Female; D005333:Fetus / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000528:radiation effects*; D006168:Guinea Pigs; D006801:Humans; D008431:Maternal-Fetal Exchange; D008954:Models, Biological; D009928:Organ Specificity; D015609:Organotechnetium Compounds / Q000009:adverse effects / Q000145:classification / Q000493:pharmacokinetics*; D011247:Pregnancy; D011264:Pregnancy Trimesters; D011829:Radiation Dosage; D011874:Radiometry / Q000379:methods / Q000592:standards; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics; D012680:Sensitivity and Specificity; D013670:Sodium Pertechnetate Tc 99m / Q000009:adverse effects / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014915:Whole-Body Counting / Q000379:methods* / Q000592:standards
D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D013670:Sodium Pertechnetate Tc 99m